The STEP1 and SURMOUNT trials demonstrated sustained clinically relevant reduction in body weight with semaglutide and tripeptide, respectively, in patients with overweight and obesity
The intervals between injections can differ based on: Absorption Capacity: If you have impaired absorption, such as in pernicious anemia, our healthcare providers may suggest more frequent injections, potentially even on a weekly basis
Unfortunately, this is not always possible
No instances of these complaints have been classified as severe [25]
For instance, patients using liraglutide (Saxenda), which is specifically approved for weight loss, typically experience average weight reductions of approximately 57% of their initial body weight after one year